ASBMR was eventful this year, with PMP osteoporosis trial news from several companies, most notably fracture data from Amgen’s denosumab and comparative BMD data from Merck’s odanacatib.
Of course, it’s easy enough for you to learn about these presentations from other news sources, so I won’t spend much time on them. Here’s the gist: Denosumab, the [...]
BBC on NICE Final Appraisal Determination for TNF-alpha inhibitors in RA
My marketing colleagues’ have generally argued that there are limited funds for studies, and such funds ought not be spent studying the competition, unless the plan is to go head to head and whoop some ass. My argument in return has been that clinical trials [...]
Results from ENHANCE are now available. I don’t think anyone is terribly surprised, given the delay in reporting the results, that addition of ezitimibe to simvasatin (i.e. Vytorin) did not have a sigificant impact on carotid intimal media thickness compared with simvastatin (Zocor) alone in subjects with heterozygous familial hypercholesterolemia (a disorder of LDL receptors that affects [...]
Genitope’s Webcast
A week ago Genitope reported the results of a pivotal Phase 3 trial for its only clinical candidate, the idiotype-specific, personalized active immunotherapy for Non-Hodgkin’s Lymphoma, known as MyVax. I’ve been interested in this budding therapy since around the time the company went public in early 2004, which roughly coincided with the start of [...]
Common virus may contribute to obesity in some people
Last September, I noted that the epidemiology of modern obesity (in the last couple decades) strongly suggests transmissible or pervasive environmental factors–more persavive even than junk food and sedentary behavior–at work in its etiology. Now, Magdalena Pasarica, M.D., Ph.D., of the Pennington Biomedical Research Center and her [...]
